For patients with chronic liver disease and type 2 diabetes, GLP1 agonist initiators associated with lower risk for major adverse liver outcomes<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Jan. 29, 2024 (HealthDay News) — For patients with chronic liver disease and type 2 diabetes, glucagon-like peptide-1 receptor (GLP1) agonists may result in a lower risk for major adverse liver outcomes (MALO), according to a study published online Jan. 22 in Gut<\/em>.<\/p>\n Axel Wester, M.D., Ph.D., from the Karolinska Institutet in Stockholm, and colleagues used observational data from Swedish health care registers from 2010 to 2020 to emulate a target trial of GLP1 agonists in eligible patients with chronic liver disease and type 2 diabetes. An inverse-probability weighted marginal structural model was used to compare parametric estimates of 10-year MALO risk in initiators of GLP1 agonists and noninitiators.<\/p>\n The researchers found that the 10-year risk for MALO was 13.3 and 14.6 percent in GLP1 agonist initiators and noninitiators, respectively, in an intention-to-treat analysis (risk ratio [RR], 0.91; 95 percent confidence interval [CI], 0.50 to 1.32). The corresponding per-protocol risk estimates at 10 years were 7.4 and 14.4 percent (RR, 0.51; 95 percent CI, 0.14 to 0.88). At six and eight years, the corresponding per-protocol risk estimates were 5.4 versus 9.0 percent (RR, 0.60; 95 percent CI, 0.29 to 0.90) and 7.2 versus 11.7 percent (RR, 0.61; 95 percent CI, 0.21 to 1.01).<\/p>\n “The risk of MALO in patients with chronic liver diseases and type 2 diabetes was lower if they initiated a GLP1 agonist and adhered to this treatment over time,” the authors write.<\/p>\n One author disclosed ties to the biopharmaceutical industry.<\/p>\n